Bravecto against fleas and ticks for dogs of very small breeds 112.5mg

DESCRIPTION

Bravecto is an insectoacaricidal drug for controlling arthropods in the form of tablets for oral administration.

In appearance, the drug is a round-shaped tablet from light brown to dark brown with a smooth or slightly rough surface, inclusions are possible.

COMPOSITION

The drug contains fluralaner 112.5mg as an active ingredient

PHARMACOLOGICAL PROPERTIES

Bravekto refers to insectoacaricidal drugs of systemic action.

Fluralaner included in the preparation - (4- [5- (3,5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl] -2-methyl-N- [2-oxo-2- (2 , 2,2-trifluoroethylamino) ethyl] benzamide) - insectoacaricide of the isoxazoline group, active against fleas (Ctenocephalides felis and Ctenocephalides canis) and ticks (adults and larvae of Ixodes ricinus, variabilis and Rhipicephalus sanguineus) parasitizing dogs.

The mechanism of action of fluralaner consists in blocking GABA-dependent and glutamate-dependent receptors in arthropods, hyperexcitation of neurons, impaired transmission of nerve impulses, which leads to paralysis and death of ectoparasites.

After oral administration of the drug, fluralaner is easily absorbed in the gastrointestinal tract and reaches the systemic circulation, the maximum plasma concentration is reached within 1 day, bioavailability is 20-27%, feed intake accelerates absorption. Fluralaner is excreted slowly, mainly in unchanged form with feces (~ 90% of the dose) and partially with urine, the half-life is 12 days.

The drug begins to act 4 hours after application and causes the death of fleas 8 hours after attachment to the host's body, ticks - after 12 hours, preventing re-infestation of dogs with ectoparasites. The death of fleas occurs before the laying of eggs, which prevents the contamination of premises with eggs and larvae.

Bravecto, in terms of the degree of impact on the body, refers to low-hazard substances (hazard class 4 according to GOST 12.1.007-76), in recommended doses it does not have an embryotoxic, teratogenic, mutagenic effect.

With the simultaneous use of Bravecto with anthelmintics, antibiotics, nonsteroidal anti-inflammatory drugs and glucocorticosteroids, no adverse reactions and a decrease in the effectiveness of the drug have been identified.

PURPOSE

The drug is prescribed to dogs for the treatment and prevention of aphanipterosis, in the complex therapy of allergic dermatitis caused by fleas, as well as acarosis caused by ixodid ticks.

APPLICATION

Bravecto is administered to dogs individually orally during or shortly before / after feeding in a therapeutic dose of 25-56 mg fluralaner per 1 kg of animal weight.

The drug has an attractive aroma and taste and is usually readily eaten by dogs; otherwise, the drug is forcibly injected directly into the mouth or fed with food. No breaking of tablets is allowed. Make sure the dog has completely swallowed the required dose.

Doses of the drug, depending on the weight of the animal and the type of tablet used, are presented in the table:

Dog weight (kg) Active ingredient dose (mg / tablet) and number of tablets

Bravecto 112.5 Bravecto 250 Bravecto 500 Bravecto 1000 Bravecto 1400

2 - 4.5 1 - - - -

4.5 - 10 - 1 - - -

10-20 - - 1 - -

20 - 40 - - - 1 -

40 - 56 - - - - 1

More than 56 A combination of two tablets is selected at the rate of 25-56 mg of fluralaner per 1 kg of animal weight

When using the drug in dogs weighing more than 56 kg, a combination of tablets is used at the rate of 25-56 mg of fluralaner per 1 kg of animal weight.

It is allowed to use the drug during pregnancy and lactation.

Repeated treatments, if necessary, are carried out after 12 weeks.

OVERDOSE

Overdose symptoms have not been identified.

SPECIAL INSTRUCTIONS

Violations of the drug use regimen should be avoided, as this can lead to a decrease in its effectiveness. In case of skipping the next treatment, the use of the drug is resumed in the same dose according to the same scheme.

CONTRAINDICATIONS

Contraindication to use is individual intolerance to the components of the drug. The drug should not be used in puppies under 8 weeks of age and / or dogs weighing less than 2 kg.

Bravecto is not intended for use by productive animals.

SIDE EFFECTS

Side effects and complications when using the drug in accordance with the instructions, as a rule, are not observed. In rare cases, vomiting, diarrhea, decreased appetite and drooling are possible. If the dog vomits within the first two hours after taking Bravecto, it is recommended to make sure that the vomiting has stopped and give the drug again in the same dose.

STORAGE

Store Bravecto in the manufacturer's sealed packaging, separately from food and feed, in a dry, dark place at a temperature from 0 В° C to 30 В° C. The shelf life of the medicinal product, subject to storage conditions, is 3 years from the date of manufacture.

PACKAGING

The drug is produced packaged in 1 tablet in blisters made of aluminum foil, placed individually in cardboard boxes along with instructions for use.

Specifications

Product subcategory

Flea and tick pills

KolVUP

ten

Manufacturer

Intervet

Temperature regime

from 0 to +30

Teaser

arthropod insectoacaricide for mini breed dogs